January 1, 2013 (Vol. 33, No. 1)
Lixte Biotechnology Holdings appointed Kathleen Mullinix, Ph.D., to its board of directors. Formerly, she was director of the office of technology and business development at Mount Sinai School of Medicine. Prior to that, Dr. Mullinix was CEO, president, and director at WellGen.
FORMA Therapeutics named Peter Wirth as chairman of its board of directors…Colorado BioScience promoted April Giles to president and CEO…Blueprint Medicines appointed Daniel S. Lynch to its board of directors as executive chairman…Amarantus BioSciences added Robert J. Zimmerman as product development advisor…PURE Bioscience hired Peter C. Wulff as CFO.
Jeff Jonas, M.D., is now president of regenerative medicine business at Shire. Formerly, he was leader of the specialty pharmaceuticals R&D team. Before joining Shire, Dr. Jonas served as evp at Isis Pharmaceuticals. Prior to this, Jeff was CMO and evp at Forest Laboratories.
Arrowhead Research appointed Robert G. Gish, M.D., as chairman of its hepatitis B clinical advisory board…Michelle Berrey, M.D., joined Chimerix as CMO…Discovery Laboratories named John R. Leone to its board of directors…Cell Therapeutics hired Monique Greer as svp, corporate communications and investor relations…immatics biotechnologies appointed Peter Chambré as chairman of its board.
Emergent BioSolutions promoted Robert G. Kramer as CFO and is also evp, corporate services division. Kramer previously was president of Emergent’s Lansing operations. Additionally, he served as the interim head of the biosciences and corporate services divisions.
Jonathan M. Fishbein, M.D., joined ReSearch Pharmaceutical Services as evp and CMO…Egenix appointed John Reid to its board of directors…Oncolytics Biotech added Kirk Look as CFO…SenGenix appointed Ralph Snyderman, M.D., as senior medical advisor and to its board of directors…Alimera Sciences added Philip Ashman, Ph.D., as svp and European managing director, Eric Teo as vp and European medical director, and Anne-Marie Swift as vp and European marketing director.
Andrew Gengos joined Immuno-Cellular Therapeutics as president and CEO. Most recently, he was president and CEO of Neuraltus Pharmaceuticals. Previously, Gengos served as vp, strategy and corporate development at Amgen. Before joining Amgen, he was at Dynavax Technologies.
Orgenesis appointed Camillo Ricordi, M.D., to its scientific advisory board…ImmunoGen hired Charles Morris as evp and chief development officer…Kristi Sarno joined Pfenex as director of business development…Lightlake Therapeutics added Kevin Pollack as CFO…Verastem appointed Alison Lawton and Michael Kauffman, M.D., Ph.D., to its board of directors…Regulus Therapeutics added Victor Knopov, Ph.D., as vp, pharmaceutical development.
Targacept hired Stephen A. Hill, M.D., as president and CEO. Previously, Dr. Hill was president and CEO of Solvay Pharmaceuticals and ArQule. Dr. Hill currently serves as non-executive chairman of the board of directors of Novelos Therapeutics and Audeo Oncology.
Immunetics hired John Yonkin as CEO…Illumina named Robert S. Epstein, M.D., to its board of directors…AAIPharma Services added David Browne as the company’s director of analytical chemistry…Cambrex named Shlomo Yanai to its board of directors…Alliqua appointed Jerome Zeldis M.D., Ph.D., as chairman of its board of directors and David Johnson as executive chairman.
Saladax Biomedical hired Mark D. Myslinski as svp and CCO. Most recently, he was president and CEO of RedPath Integrated Pathology. Previously, Myslinski served as vp of evidence-based medicine at Ortho Clinical Diagnostics and general manager at Veridex.
Tris Pharma hired Jonathan Berlent as vp of business development…Definiens named Gerald Möller, Ph.D., as chairman of its supervisory board…Craig Loftus joined Sygnature Discovery as vp, business development North America…CombiMatrix appointed Jeremy M. Jones to its board of directors…Julie Hambleton, M.D., joined FivePrime Therapeutics as svp and CMO…ImmunoCellular Therapeutics hired Andrew Gengos as CEO…Kane Biotech appointed Arvind K. Joshi, M.D., to its board of directors.
Cambridge Major Laboratories added Prasad Raje, Ph.D., as vp of science and technology. Prior to joining CML, he was president of Smithers Pharma Services. Previously, Dr. Raje was president and managing director of AMRI India. He started his career as a senior research scientist at Abbott Laboratories.
Sorbent Therapeutics added Jason Levin as CBO…Peptides International promoted Michael Pennington, Ph.D., as president and CEO…Prosonix elected Ken Cunningham, M.D., as nonexecutive chairman…Innova Biosciences named Andrew Lane, Ph.D., as executive director of its board and Tim Bernard as chairman…Histogenics appointed Kevin L. Rakin to its board of directors.
Send your People Announcements to [email protected]